Shares of Akebia Therapeutics Inc. (NASDAQ:AKBA) rose 2.5% during mid-day trading on Monday . The stock traded as high as $8.35 and last traded at $8.15, with a volume of 96,662 shares changing hands. The stock had previously closed at $7.95.

AKBA has been the topic of several recent research reports. Morgan Stanley reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research report on Sunday, May 8th. Brean Capital reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research report on Sunday, May 8th. Zacks Investment Research lowered Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 10th. HC Wainwright reiterated a “buy” rating on shares of Akebia Therapeutics in a report on Monday, May 16th. Finally, Credit Suisse Group AG reiterated a “hold” rating on shares of Akebia Therapeutics in a report on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $15.75.

The stock has a 50-day moving average price of $8.44 and a 200 day moving average price of $8.46. The stock’s market capitalization is $153.54 million.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.38. Equities research analysts forecast that Akebia Therapeutics Inc. will post ($3.73) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Akebia Therapeutics stock. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Akebia Therapeutics Inc. (NASDAQ:AKBA) by 9.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 97,925 shares of the biopharmaceutical company’s stock after buying an additional 8,500 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.54% of Akebia Therapeutics worth $1,265,000 as of its most recent SEC filing.

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.